Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Learn more about whether Glaukos Corporation or Omnicell, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived ...

Minot Light Capital Partners, an investment management company, released its Q3 2025 investment letter. A copy of the letter ...

CytomX Therapeutics, Inc. is downgraded to Hold ahead of key CX-2051 Phase 1 expansion data in 1Q26. Learn more about CTMX ...

Chronic sleep deprivation acts as a systemic stressor, elevating risks for cardiovascular disease and metabolic dysregulation while impairing cognitive function.

It seems that every day brings a new artificial intelligence solution to health care, with providers able to automate myriad ...

AHA's 2026 Environmental Scan highlights financial constraints, workforce strain and shifting demand patterns no longer are emerging issues — they are persistent conditions shaping daily operations ...

The Goldman Sachs Mid Cap Growth Fund underperformed its benchmark, the Russell Midcap Growth Index (net), during the quarter ...

GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight. But they need to be taken for years, ...

As part of conversations between AI healthcare leaders on the podcast AI Amplified this year, a clear picture emerged of where artificial intelligence is genuinely transforming healthcare — and where ...